NYSE: SRXH

SRx Health Solutions, Inc.

CIK 0001471727 · SIC 2080 · Beverages

Micro Revenue $7M Assets $145M as of Aug 23, 2026

Health Solutions Inc. (“SRx” or the “Company”) is the successor reporting entity following a reverse merger with Better Choice Company, Inc. (“Better Choice” or “BTTR”), the pet health and wellness business. About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (IREN 10-K) is open in full — no account needed.

8-K Filed Aug 28, 2026 · Period ending Aug 27, 2026

Summary not yet generated.

8-K Filed Aug 19, 2026 · Period ending Aug 13, 2026

Summary not yet generated.

Partner

Trade SRXH commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-Q Filed Aug 13, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

8-K Filed Jul 28, 2026 · Period ending Jul 27, 2026

Summary not yet generated.

8-K Filed Jul 21, 2026 · Period ending Jul 17, 2026

Summary not yet generated.

8-K Filed Jul 16, 2026 · Period ending Jul 15, 2026

Summary not yet generated.

424B3 Filed Jul 16, 2026

Summary not yet generated.

424B3 Filed Jul 16, 2026

Summary not yet generated.

8-K Filed Jul 15, 2026 · Period ending Jul 14, 2026

Summary not yet generated.

8-K Filed Jul 10, 2026 · Period ending Jul 8, 2026

Summary not yet generated.

8-K Filed Jun 26, 2026 · Period ending Jun 26, 2026

Summary not yet generated.

8-K Filed Jun 24, 2026 · Period ending Jun 23, 2026

Summary not yet generated.

8-K Filed Jun 18, 2026 · Period ending Jun 18, 2026

Summary not yet generated.

424B3 Filed Jun 8, 2026

Summary not yet generated.

424B3 Filed Jun 8, 2026

Summary not yet generated.

10-Q Filed May 14, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

8-K Filed Apr 22, 2026 · Period ending Apr 22, 2026

Summary not yet generated.

8-K Filed Apr 17, 2026 · Period ending Apr 17, 2026

Summary not yet generated.

8-K Filed Mar 18, 2026 · Period ending Mar 16, 2026

Summary not yet generated.

10-Q Filed Feb 13, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-K Filed Dec 5, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

10-K Filed Mar 31, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed Aug 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations (Unaudited)

(Dollars in thousands, except share and per share amounts)

Description Three months ended June 30, 2026 Three months ended June 30, 2025 Nine months ended June 30, 2026 Nine months ended June 30, 2025
Net sales 3,392 2,673 9,638 2,673
Cost of goods sold 2,488 2,642 6,405 2,642
Gross profit 904 31 3,233 31
Operating expenses:
Selling, general and administrative 4,105 8,637 12,042 8,637
Loss from continuing operations (3,201) (8,606) (8,809) (8,606)
Other expense (income):
Interest expense, net 569 (30) 3,637 (30)
Loss/(Gain) on extinguishment of debt (469) 2,588
Change in fair value of digital assets 1,410 4,768
Change in fair value of equity securities (12) 481
Change in fair value of derivative liabilities (578) (1,170)
Bargain purchase gain (1,693) (1,693)
Other income, net 19 (32) 16 (32)
Total other expense, net 939 (1,755) 10,320 (1,755)
Net loss before income taxes (4,140) (6,851) (19,129) (6,851)
Income tax expense 6
Net loss from continuing operations (4,140) (6,851) (19,135) (6,851)
Loss from discontinued operations (8,282) (22,894)
Net loss (4,140) (15,133) (19,135) (29,745)
Weighted average number of shares outstanding, basic 11,420,008 340,019 5,629,712 322,245
Weighted average number of shares outstanding, diluted 11,420,008 340,019 5,629,712 322,245
Loss per share, basic (0.36) (44.51) (3.40) (92.31)
Loss per share, diluted (0.36) (44.51) (3.40) (92.31)

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands, except share and per share amounts)

Description June 30, 2026 September 30, 2025
Assets
Current Assets
Cash and cash equivalents 35,186 1,309
Restricted cash 1,500
Short-term investments 7,502
Accounts receivable, net 3,629 3,945
Inventories, net 2,611 2,078
Notes receivable 4,940
Digital assets 2,120
Investment in equity securities 5,500
Prepaid expenses and other current assets 2,254 794
Total Current Assets 65,242 8,126
Fixed assets, net 9 88
Intangible assets, net 79,981
Right-of-use assets, operating leases 20
Other assets 125 168
Total Assets 145,357 8,402
Liabilities & Stockholders’ Equity
Current Liabilities
Accounts payable 1,277 2,147
Accrued liabilities 1,091 1,375
Operating lease liability, short-term 21
Total Current Liabilities 2,368 3,543
Convertible debt, long-term 4,452
Total Liabilities 2,368 7,995
Stockholders’ Equity
Common Stock, $0.001 par value, 5,000,000,000 shares authorized, 19,517,637 & 416,542 shares issued and outstanding as of June 30, 2026, and September 30, 2025, respectively 1,174 31
Preferred Stock, $0.001 par value, 4,000,000 shares authorized, 5,660 & zero shares issued and outstanding as of June 30, 2026 and September 30, 2025, respectively
Additional paid-in capital, common stock 180,717 23,304
Additional paid-in capital, preferred stock 3,161
Accumulated deficit (42,063) (22,928)
Total Stockholders’ Equity 142,989 407
Total Liabilities and Stockholders’ Equity 145,357 8,402

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

Description Nine months ended June 30, 2026 Nine months ended June 30, 2025
Cash Flow from Operating Activities:
Net loss (19,135) (6,851)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization (46) 309
Non-cash fixed assets adjustment 75
Bargain purchase gain (1,693)
Gain on disposal of assets, net (13)
Share-based compensation 961 2,032
Debt discount amortization 3,320
Equity offering-related parties 3,342
Bad debt expense (39)
Income tax provision 6
Change in fair value of digital assets 4,768
Change in fair value of equity securities 481
Change in fair value of derivative liabilities (1,170)
Loss on settlement of debt 2,588
Other (1) 2
Changes in operating assets and liabilities:
Accounts receivable, net 355 460
Inventories, net (533) 624
Prepaid expenses and other assets (1,417) (773)
Accounts payable (870) (594)
Accrued liabilities 165 1,369
Cash Used in Operating Activities (10,505) (1,773)
Cash Flow from Investing Activities:
Acquisition of EMJX (306)
Short-term investments, net (7,502)
Purchase of digital assets (16,468)
Proceeds from sale of digital assets 9,580
Purchase of equity securities (5,240)
Proceeds from sale of equities and option contracts (active trades) 159,200
Purchases of equities and option contracts (active trades) (158,575)
Purchase of convertible note receivable (6,377)
Cash paid to SRx Canada (3,400)
Proceeds from sale of convertible note receivable 1,500
Cash Used in Investing Activities (24,188) (3,400)
Cash Flow from Financing Activities:
Proceeds from issuance of common stock 80,335
Proceeds from issuance of convertible preferred stock 13,440
Redemption of Series A convertible preferred stock (21,773)
Repayment of convertible debt (1,623)
Cash paid for financing costs (625)
Proceeds from warrant exercises 323
Repurchase of common stock (7)
Proceeds from short-term borrowings 550
Proceeds from Wintrust facility 859
Payments on Wintrust facility (1,662)
Proceeds from PIPE 8,800
PIPE out (8,800)
Payments for share repurchase (137)
Cash Provided by (Used in) Financing Activities 70,070 (390)
Net cash provided by (used in) continuing operations 35,377 (5,563)
Net cash provided by discontinued operations 6,253
Net increase in cash and cash equivalents 35,377 690
Effect of foreign currency translation adjustments 116
Total cash and cash equivalents, beginning of period 1,309 106
Total cash and cash equivalents, end of period 36,686 912
Supplemental schedule of cash flow information:
Cash paid for interest
Disclosure of non-cash financing activities:
Convertible note settled via reduction in equity consideration 1,705

Amounts as printed on the EDGAR/iXBRL face — (Dollars in thousands, except share and per share amounts); (Dollars in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About SRx Health Solutions, Inc.

Source: Item 1 (Business) from the 10-K filed December 5, 2025. Description as filed by the company with the SEC.

1. BUSINESS

History

Health Solutions Inc. (“SRx” or the “Company”) is the successor reporting entity following a reverse merger with
Better Choice Company, Inc. (“Better Choice” or “BTTR”), the pet health and wellness business.

Historically,
SRx was engaged in specialty pharmaceuticals and healthcare services, including a series of acquisitions to expand its operations. These
legacy operations faced financial difficulties and subsequently filed for bankruptcy, resulting in the winding down of the majority of
SRx’s former business. These legacy operations are reported as discontinued operations in the financial statements.

Continuing
Operations

Company’s continuing operations consist of the pet health and wellness business formerly operated by Better Choice. This business
is focused on providing high-quality pet products under the Halo brand, including foods, treats, toppers, dental products, chews, and
supplements for dogs and cats.

Better
Choice’s products are sold across multiple channels: e-commerce platforms such as Amazon and Chewy, select retail partners, and
international distributors. The direct-to-consumer channel through halopets.com was exited in June 2024, and consumers are now directed
to retail partners for online purchase.

Company continues to operate this business post-RTO, including managing product innovation, brand positioning, and supply chain relationships
with co-manufacturers. The Halo portfolio includes Halo Holistic™ and Halo Elevate®, designed for pet parents seeking high-quality,
science-based nutrition for their pets.

Read full description ↓

Products
and Brands — Continuing Operations

continuing operations include over 100 premium and super-premium pet health and wellness products across multiple forms, including kibble,
canned food, freeze-dried raw food, treats, and supplements. All products are formulated to meet high-quality sourcing and nutritional
standards, leveraging longstanding co-manufacturing relationships.

Discontinued
Operations

Company’s legacy specialty pharmaceuticals and healthcare services operations, historically conducted under SRx, are classified
as discontinued operations following the Company’s bankruptcy and subsequent winding down of these activities.

Historically,
SRx provided specialty pharmaceutical products and related services to healthcare providers and patients across various therapeutic areas.
Over time, the Company pursued acquisitions and expansion strategies aimed at growing its product portfolio and market presence.

Due
to financial challenges, SRx filed for bankruptcy, resulting in the termination, sale, or wind-down of its operations. As of the reporting
date, the legacy SRx business no longer generates meaningful revenue or operational activity.

Financial
results of the discontinued operations are reported separately in the consolidated financial statements, in accordance with accounting
guidance for discontinued operations, and include any final settlements, asset disposals, and associated liabilities. The Company does
not expect future cash flows from these operations.

Customers and Channels

For
the year ended September 30, 2025, the Company’s continuing operations, conducted through Better Choice, generated net sales of
approximately $6.5 million. The Company primarily serves pet owners through three main channels: E-commerce, Brick & Mortar, and
International.

E-commerce:
The majority of continuing net sales are generated through E-commerce partner websites, including Amazon, Chewy, Petflow, Thrive Market,
and Vitacost. Online sales are largely driven by repeat purchases from existing customers, reflecting strong brand loyalty.

Brick
& Mortar: Sales through physical retailers primarily include specialty pet stores and select grocery chains. As of December 2023,
the Company strategically exited Petco and Pet Supplies Plus stores while continuing online sales via those platforms.

International:
Halo’s international sales represent a smaller portion of total net sales. Following the sale of Halo Asia, international operations now contribute only a limited amount of revenue, and
the Company’s activities outside North America are no longer a significant growth focus. As a result, no single foreign market represents
a material share of international revenue.

majority of net sales are generated online, reflecting both the Company’s focus on digital channels and consumer preference for
online purchasing. The Company’s ability to reach a growing base of diverse customers online is expected to improve as E-commerce
penetration increases.

Discontinued
Operations

Company’s legacy SRx business, which historically provided specialty pharmaceuticals and healthcare services, is reported as discontinued
operations following its bankruptcy and wind-down. SRx no longer generates meaningful revenue, and prior period comparatives related
to SRx are presented separately in the financial statements.

Supply
Chain, Manufacturing and Logistics

Halo
partners with a number of co-manufacturing partners to produce its products. Products sold today under the Halo brand are made strictly
from naturally raised animals on sustainable farms and are manufactured in the U.S and use healthy, natural ingredients, with all purchases
transacted in U.S. dollars. By sourcing cage-free poultry, pasture-raised beef, and wild-caught fish from certified sustainable fisheries
and not including meat meals or other animal byproducts in its formulations, our Halo brand is able to provide pets and pet parents with
a nutritious and highly digestible suite of food and treats. Some products are preserved using either freeze drying or gentle air dehydration
to eliminate the need for artificial preservatives and added chemicals. Our treats and chews are oven-baked, using natural ingredients
for maximum nutrition and protein content. Halo’s dog and cat foods meet The Association of American Feed Control Officials (“AAFCO”)
guidelines and are small-batch tested for common contaminants prior to leaving the manufacturer.

utilize logistics service providers as a part of our supply chain, primarily for shipping and logistics support. Fulfillment of orders
is managed by a third-party warehousing and logistics partner, Fidelitone. Our warehouse is located in Wauconda, Illinois. Our products
are shipped by trusted carriers for expeditious and reliable delivery.

Raw
Materials and Principal Suppliers

rely upon the supply of raw materials that meet our high-quality specifications and sourcing requirements. We source Global Animal Partnership
(“GAP”) certified cage-free chicken, GAP certified cage-free turkey, Marine Stewardship Council (“MSC”) certified
wild-caught salmon and whitefish and select non-GMO fruits and vegetables, such as peas, sweet potatoes and lentils. If any raw material
is adulterated and does not meet our specifications, it could significantly impact our ability to source manufactured products and could
materially and adversely impact our business, financial condition and results of operations.

For
the supply and co-manufacturing of our products, we have relied on: Alphia, Inc. (“Alphia” f/k/a “C.J. Foods”)
for dry kibble which transitioned to Barrett Petfood Innovations during 2022, then back to Alphia during 2023; Simmons Pet Food, Inc.
(“Simmons”) and Thai Union Manufacturing Co., LTD. for canned wet food; BrightPet Nutrition Group, LLC (“BrightPet”)
for vegan kibble and freeze dried treats; Carnivore Meat Company, LLC (“Carnivore”) for the supply and co-manufacturing of
freeze-dried food and treats. We sourced approximately 85% of its inventory purchases from three vendors for the year ended September
30, 2025.

Sales
and Marketing

marketing strategies are designed to clearly communicate to consumers about the benefits of our products and to build awareness of our
brands. We deploy a broad set of marketing tools across various forms of media to reach consumers through multiple touch points and engage
with a number of marketing agencies to develop content and product packaging. Our marketing initiatives include the use of social and
digital marketing, Search Engine Optimization, email and SMS marketing, and paid media (Facebook, Instagram & YouTube), among other
proven strategies to generate and convert sales prospects into loyal, satisfied customers. In addition to directly targeting and educating
consumers of our products, we partner with a number of retailers such as Amazon, Chewy and Petco to develop joint sales and marketing
initiatives to increase sales and acquire new customers.

In
recent years, consumer purchasing behaviors have shifted dramatically and E-Commerce penetration has significantly increased. In the
fourth quarter of 2023, management shifted from a Brick & Mortar channel focus to a digital first strategy as a result of its annual
operating plan process and has strategically reallocated marketing investments to work more effectively and efficiently in its larger
e-commerce platforms to drive growth and brand awareness.

Competition

pet health and wellness industry is highly competitive. Competitive factors include product quality, ingredients, brand awareness and
loyalty, product variety, product packaging and design, reputation, price, advertising, promotion, and nutritional claims. We believe
that we compete effectively with respect to each of these factors. We compete with manufacturers of conventional pet food such as Mars,
Nestlé and Big Heart Pet Brands (part of the J.M. Smucker Company), and manufacturers of specialty and natural pet food such as
Blue Buffalo (part of General Mills), Wellness, Fromm, Orijen, Merrick (part of Nestlé), Stella and Chewy, Open Farm and Freshpet.
In addition, we compete with many regional niche brands in individual geographic markets.

Employees
and Human Capital Resources

As
of September 30, 2025, we had 10 full time employees and one part time employee. Our human capital resource objectives include, as applicable,
identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our
equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based
compensation awards. Our employees are not represented by any labor union or any collective bargaining arrangement with respect to their
employment with us. We have never experienced any work stoppages or strikes as a result of labor disputes and we believe our overall
relationships with our employees are positive and the strength of our team is a critical success factor in becoming the most innovative
premium pet food company in the world. Our employees share an entrepreneurial spirit, a passion for excellence and the inspiration to
drive the future of the pet health and wellness industry.

core values are Integrity, Respect, Working Smarter and Faster and Building Lasting Relationships in all that we do. We continually focus
on employee engagement and a diverse, inclusive culture in order to ensure the continued strength and well-being of our workforce. We
strive to create a workplace where employees feel engaged, believe in our mission, understand their role in our strategy and are passionate
about the work they do. We conduct employee engagement surveys to provide us with valuable insights into employee perspectives and experiences.
We also hold frequent virtual town-hall meetings and team building events to provide updates, celebrate milestones in the business, communicate
initiatives, recognize significant individual accomplishments and provide a forum for employees to communicate and engage with our entire
employee base. We value and embrace diversity by fostering a culture that encompasses the unique attributes, ideas, perspectives, and
experiences of our employees, customers, suppliers and communities. We believe a more inclusive and diverse work environment allows us
to achieve better results and makes us a stronger business.

operate under a “Win From Anywhere” culture, which is our approach to creating a flexible and entrepreneurial working environment
built for long term success. Winning from anywhere means our employees can work from anywhere in the country. We believe this culture
provides the ability for us to attract the best talent and we now have employees all over the U.S. that are winning from anywhere.

Government
Regulation

regulation of animal food products is complex, multi-faceted, and continually changing. The U.S. Food and Drug Administration (“FDA”),
the U.S. Federal Trade Commission (“FTC”), the U.S. Department of Agriculture (“USDA”) and other regulatory authorities
at the federal, state and local levels, as well as authorities in foreign countries, extensively regulate, among other things, the research,
development, testing, composition, manufacture, import, export, labeling, storage, distribution, promotion, marketing, and post-market
reporting of animal foods. We are required to navigate a complex regulatory framework in the locations in which we wish to manufacture,
test, import, export, or sell our products.

FDA
Regulation of Animal Foods

FDA regulates foods, including foods intended for animals, under the Federal Food, Drug and Cosmetic Act (“FDCA”) and its
implementing regulations. The FDCA defines “food” as articles used for food or drink for man or other animals, which includes
products that are intended primarily for nutritional use, taste, or aroma and the components of such products. For animal foods in particular,
this definition applies based on their intended use regardless of labelling as animal food, treats, or supplements. The FDA also imposes
certain requirements on animal foods relating to their composition, manufacturing, labeling, and marketing. Among other things, the facilities
in which our products and ingredients are manufactured must register with the FDA, comply with current good manufacturing practices (“cGMPs”)
and comply with a range of food safety requirements.

Although
pet foods are not required to obtain premarket approval from the FDA, any substance that is added to or is expected to become a component
of a pet food must be used in accordance with a food additive regulation, unless it is generally recognized as safe (“GRAS”)
under the conditions of its intended use or if it appears on an FDA-recognized list of acceptable animal food ingredients in the Official
Publication of AAFCO. A food may be adulterated if it uses an ingredient that is neither GRAS nor an approved food additive, and that
food may not be legally marketed in the U.S.

labeling of pet foods is regulated by both the FDA and state regulatory authorities. FDA regulations require proper identification of
the product, a net quantity statement, a statement of the name and place of business of the manufacturer or distributor and proper listing
of all the ingredients in order of predominance by weight. The FDA also considers certain specific claims on pet food labels to be medical
claims and therefore subject to prior review and approval by the FDA. The FDA has a list of specific factors it will consider in determining
whether to initiate enforcement action against such products if they do not comply with the regulatory requirements applicable to drugs,
including, among other things, whether the product is only made available through or under the direction of a veterinarian and does not
present a known safety risk when used as labeled. The FDA may classify some of our products differently than we do and may impose more
stringent regulations which could lead to possible enforcement action.

Under
the FDCA, the FDA may require the recall of an animal food product if there is a reasonable probability that the product is adulterated
or misbranded, and the use of or exposure to the product will cause serious adverse health consequences or death. In addition, pet food
manufacturers may voluntarily recall or withdraw their products from the market. If the FDA believes that our products are adulterated,
misbranded or otherwise marketed in violation of the FDCA, the agency make take further enforcement action, including: restrictions on
the marketing or manufacturing of a product; required modification of promotional materials or issuance of corrective marketing information;
issuance of safety alerts, press releases, or other communications containing warnings or other safety information about a product; warning
or untitled letters; product seizure or detention; refusal to permit the import or export of products; fines, injunctions, or consent
decrees; and/or imposition of civil or criminal penalties.

Corporate
Information

were incorporated in the State of Nevada in 2001 under the name Cayenne Construction, Inc., and in 2009, changed our name to Sports Endurance,
Inc. Effective March 11, 2019, we changed our name to Better Choice Company Inc. after reincorporating in Delaware and effective April
24, 2025, we changed our name to SRx Health Solutions, Inc. We have five wholly owned subsidiaries - Halo, Purely for Pets, Inc., Bona
Vida, Inc., Aimia Pet Healthco Inc, SRx Health Solutions (Canada), Inc., and 1000994085 Ontario Inc. Our principal executive offices
are located at 801 US Highway 1, North Palm Beach, Florida 33408. Our website is available at https://www.srxhealth.com. Our website
and the information contained on or connected to that site are not, and should not be deemed to be part of or incorporated into this
prospectus.

Available
Information

file annual, quarterly and current reports and other information with the SEC that are publicly available at www.sec.gov. Our
SEC filings are also available under the Investor Relations section of our website at www.srxhealth.com as soon as reasonably
practicable after they are filed with or furnished to the SEC. Information contained on or connected to our website are not incorporated
into this Annual Report on Form 10-K.